BCL2L11 and breast carcinoma: Bean GR et al. demonstrated that PUMA and BIM were the key apoptotic effectors of tyrosine kinase inhibitors in breast cancers with overexpression of HER2 by directly activating Bak to permeabilize mitochondria leading to caspase activation and apoptosis [26].